Edition:
India

Eloxx Pharmaceuticals Inc (ELOX.OQ)

ELOX.OQ on NASDAQ Stock Exchange Global Market

4.14USD
11 Oct 2019
Change (% chg)

$0.58 (+16.29%)
Prev Close
$3.56
Open
$3.62
Day's High
$4.32
Day's Low
$3.60
Volume
46,854
Avg. Vol
40,795
52-wk High
$17.50
52-wk Low
$3.21

Latest Key Developments (Source: Significant Developments)

Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation To Provide Funding And Support For ELX-02 U.S. Phase 2 Clinical Trial
Monday, 23 Sep 2019 

Sept 23 (Reuters) - Eloxx Pharmaceuticals Inc ::ELOXX PHARMACEUTICALS ANNOUNCES CYSTIC FIBROSIS FOUNDATION (CF FOUNDATION) TO PROVIDE FUNDING AND SUPPORT FOR ELX-02 U.S. PHASE 2 CLINICAL TRIAL.ELOXX PHARMACEUTICALS INC - ON TRACK TO REPORT TOP LINE PHASE 2 DATA FOR ELX-02 IN CYSTIC FIBROSIS AND CYSTINOSIS IN 2019.ELOXX PHARMACEUTICALS INC - ANTICIPATES REPORTING TOP LINE DATA IN Q4 OF 2019..  Full Article

Eloxx Pharmaceuticals Reports Q2 LOSS PER SHARE $0.40
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Eloxx Pharmaceuticals Inc ::ELOXX PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE $0.40.Q2 EARNINGS PER SHARE ESTIMATE $-0.36 -- REFINITIV IBES DATA.ON TRACK TO REPORT TOP LINE DATA FROM PHASE 2 CLINICAL TRIALS FOR ELX-02 IN CYSTIC FIBROSIS AND CYSTINOSIS.INITIATED A PHASE 2 CLINICAL TRIAL FOR ELX-02 IN CYSTINOSIS IN CANADA.PHASE 2 CYSTIC FIBROSIS CLINICAL TRIAL IND IS OPEN IN U.S..EXPECT TO REPORT TOP LINE DATA IN CYSTINOSIS EARLY IN Q4 OF 2019.AS OF JUNE 30, 2019, WE HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $76.3 MILLION.  Full Article

Eloxx Pharmaceuticals Announces Initiation Of Phase 2 Clinical Trial For Elx-02 In Cystinosis
Monday, 5 Aug 2019 

Aug 5 (Reuters) - Eloxx Pharmaceuticals Inc ::ELOXX PHARMACEUTICALS ANNOUNCES INITIATION OF PHASE 2 CLINICAL TRIAL FOR ELX-02 IN CYSTINOSIS.ELOXX PHARMACEUTICALS ANNOUNCES INITIATION OF PHASE 2 CLINICAL TRIAL FOR ELX-02 IN CYSTINOSIS.ELOXX PHARMACEUTICALS - ON TRACK TO REPORT TOP LINE DATA FROM PHASE 2 CLINICAL TRIALS FOR ELX-02 IN CYSTIC FIBROSIS & CYSTINOSIS IN U.S., EUROPE, ISRAEL & CANADA IN 2019.  Full Article

Eloxx Pharmaceuticals Says Offering Of Common Shares Priced At $9.00/Share
Thursday, 20 Jun 2019 

June 20 (Reuters) - Eloxx Pharmaceuticals Inc ::ELOXX PHARMACEUTICALS ANNOUNCES PRICING OF $30.0 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 3.33 MILLION COMMON SHARES PRICED AT $9.00PER SHARE.  Full Article

Eloxx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Thursday, 20 Jun 2019 

Eloxx Pharmaceuticals Inc ::ELOXX PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ELOXX PHARMACEUTICALS- ANTICIPATES USING NET PROCEEDS FROM OFFERING TO FUND CONTINUED CLINICAL DEVELOPMENT OF ELX-02 IN CYSTIC FIBROSIS, CYSTINOSIS.ELOXX PHARMACEUTICALS - ANTICIPATES USING NET PROCEEDS TO FUND CONTINUED CLINICAL DEVELOPMENT OF ELX-02 IN CYSTIC FIBROSIS AND CYSTINOSIS.  Full Article

Eloxx Pharmaceuticals Reports Q1 Results
Thursday, 9 May 2019 

May 9 (Reuters) - Eloxx Pharmaceuticals Inc ::ELOXX PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.33.Q1 EARNINGS PER SHARE ESTIMATE $-0.41 -- REFINITIV IBES DATA.AS OF MARCH 31, 2019, CO HAD CASH AND CASH EQUIVALENTS OF $53.5 MILLION.ELOXX PHARMACEUTICALS - ON TRACK TO REPORT TOP LINE DATA FROM PHASE 2 CLINICAL TRIALS FOR ELX-02 IN CYSTIC FIBROSIS, CYSTINOSIS IN U.S., EUROPE IN 2019.  Full Article

Eloxx Pharmaceuticals Reports Q4 Loss Per Share Of $0.40
Friday, 8 Mar 2019 

March 8 (Reuters) - Eloxx Pharmaceuticals Inc ::ELOXX PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.40.Q4 EARNINGS PER SHARE ESTIMATE $-0.34 -- REFINITIV IBES DATA.ON TRACK TO REPORT TOP LINE DATA FROM A PHASE 2 CLINICAL TRIAL FOR ELX-02 IN CYSTIC FIBROSIS IN U.S. AND EUROPE IN 2019.ELOXX PHARMACEUTICALS - EXPECT TOTAL CASH AND CASH EQUIVALENTS, INCLUDING NET DEBT PROCEEDS, WILL BE SUFFICIENT TO FUND OPERATIONS INTO Q2 OF 2020.AS OF DEC 31, 2018 CASH AND CASH EQUIVALENTS OF $48.6 MILLION.  Full Article

Eloxx Pharmaceuticals Says Entered Into A Loan And Security Agreement, Dated As Of January 30, 2019
Saturday, 2 Feb 2019 

Feb 1 (Reuters) - Eloxx Pharmaceuticals Inc ::ELOXX PHARMACEUTICALS INC - ENTERED INTO A LOAN AND SECURITY AGREEMENT, DATED AS OF JANUARY 30, 2019 - SEC FILING.ELOXX PHARMACEUTICALS INC - LENDERS AGREED TO EXTEND TERM LOANS TO THE COMPANY IN AN AGGREGATE PRINCIPAL AMOUNT OF UP TO $25 MILLION.  Full Article

Eloxx Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln
Saturday, 17 Nov 2018 

Nov 16 (Reuters) - Eloxx Pharmaceuticals Inc ::ELOXX PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING.  Full Article

Eloxx Pharmaceuticals Announces Orphan-Drug Designation For ELX-02 For Treatment Of Cystinosis
Friday, 27 Apr 2018 

April 27 (Reuters) - Eloxx Pharmaceuticals Inc ::ELOXX PHARMACEUTICALS ANNOUNCES FDA GRANT OF ORPHAN-DRUG DESIGNATION FOR INVESTIGATIONAL DRUG ELX-02 FOR TREATMENT OF CYSTINOSIS.  Full Article